LU83081A1 - Compositions antitumeurs - Google Patents
Compositions antitumeurs Download PDFInfo
- Publication number
- LU83081A1 LU83081A1 LU83081A LU83081A LU83081A1 LU 83081 A1 LU83081 A1 LU 83081A1 LU 83081 A LU83081 A LU 83081A LU 83081 A LU83081 A LU 83081A LU 83081 A1 LU83081 A1 LU 83081A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- anisidide
- methanesulfone
- acridinylamino
- organic acid
- gluconolactone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 46
- 230000000259 anti-tumor effect Effects 0.000 title description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 52
- -1 9-acridinylamino Chemical group 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 229960003681 gluconolactone Drugs 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 29
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 28
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 28
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 27
- 235000012208 gluconic acid Nutrition 0.000 claims description 27
- 239000000174 gluconic acid Substances 0.000 claims description 26
- 150000007524 organic acids Chemical class 0.000 claims description 23
- 229940050410 gluconate Drugs 0.000 claims description 18
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 239000008135 aqueous vehicle Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229950006191 gluconic acid Drugs 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241001342522 Vampyrum spectrum Species 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11480980A | 1980-01-24 | 1980-01-24 | |
| US11480980 | 1980-01-24 | ||
| US06/194,350 US4322424A (en) | 1980-01-24 | 1980-10-17 | Crystalline glucoconate salt of m-AMSA and compositions containing same |
| US19435080 | 1980-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU83081A1 true LU83081A1 (fr) | 1981-09-10 |
Family
ID=26812557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU83081A LU83081A1 (fr) | 1980-01-24 | 1981-01-23 | Compositions antitumeurs |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4322424A (en, 2012) |
| AT (1) | AT380474B (en, 2012) |
| AU (1) | AU543758B2 (en, 2012) |
| CA (1) | CA1252103A (en, 2012) |
| CH (1) | CH648023A5 (en, 2012) |
| DE (1) | DE3102026A1 (en, 2012) |
| DK (1) | DK29781A (en, 2012) |
| FI (1) | FI79840C (en, 2012) |
| FR (1) | FR2474493B1 (en, 2012) |
| GB (1) | GB2068729B (en, 2012) |
| GR (1) | GR82326B (en, 2012) |
| IE (1) | IE50884B1 (en, 2012) |
| IT (1) | IT1170638B (en, 2012) |
| LU (1) | LU83081A1 (en, 2012) |
| NL (1) | NL8100292A (en, 2012) |
| SE (1) | SE453497B (en, 2012) |
| YU (1) | YU42552B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU186383B (en) * | 1981-02-27 | 1985-07-29 | Biogal Gyogyszergyar | Process for producing new citostatic amni-acridie-alpha, beta-bracket-d-bracket closed, or aracket-l-bracket closed-n-glycoside derivatives and salts |
| US4575509A (en) * | 1983-01-31 | 1986-03-11 | Bristol-Myers Company | Water-soluble formulations of m-AMSA with pyroglutamic acid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1674923A (en) * | 1924-04-12 | 1928-06-26 | Schnorf Carl | Process for the production of carbohydrate-acridine compounds and solutions thereof |
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| US4258191A (en) * | 1979-03-29 | 1981-03-24 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Multi-step process for the production of methanesulfon-m-anisidide, 4'-(9-acridinylamino)- |
| AU534608B2 (en) * | 1979-09-14 | 1984-02-09 | Warner-Lambert Corporation | Compounds having antitumour properties |
| ZA811304B (en) * | 1980-03-11 | 1982-06-30 | Warner Lambert Co | Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide |
-
1980
- 1980-10-17 US US06/194,350 patent/US4322424A/en not_active Expired - Lifetime
-
1981
- 1981-01-20 YU YU145/81A patent/YU42552B/xx unknown
- 1981-01-21 SE SE8100341A patent/SE453497B/sv not_active IP Right Cessation
- 1981-01-21 IT IT47604/81A patent/IT1170638B/it active
- 1981-01-21 NL NL8100292A patent/NL8100292A/nl not_active Application Discontinuation
- 1981-01-21 AU AU66512/81A patent/AU543758B2/en not_active Ceased
- 1981-01-22 CA CA000369109A patent/CA1252103A/en not_active Expired
- 1981-01-22 DK DK29781A patent/DK29781A/da not_active Application Discontinuation
- 1981-01-22 DE DE19813102026 patent/DE3102026A1/de active Granted
- 1981-01-22 FI FI810180A patent/FI79840C/fi not_active IP Right Cessation
- 1981-01-23 GB GB8102175A patent/GB2068729B/en not_active Expired
- 1981-01-23 GR GR63955A patent/GR82326B/el unknown
- 1981-01-23 IE IE119/81A patent/IE50884B1/en unknown
- 1981-01-23 LU LU83081A patent/LU83081A1/fr unknown
- 1981-01-23 FR FR8101233A patent/FR2474493B1/fr not_active Expired
- 1981-01-26 AT AT0032681A patent/AT380474B/de not_active IP Right Cessation
- 1981-01-26 CH CH484/81A patent/CH648023A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3102026A1 (de) | 1982-03-04 |
| GB2068729A (en) | 1981-08-19 |
| AU543758B2 (en) | 1985-05-02 |
| FI79840C (fi) | 1990-03-12 |
| CA1252103A (en) | 1989-04-04 |
| DE3102026C2 (en, 2012) | 1990-05-31 |
| IE810119L (en) | 1981-07-24 |
| AU6651281A (en) | 1981-07-30 |
| YU42552B (en) | 1988-10-31 |
| DK29781A (da) | 1981-07-25 |
| FR2474493B1 (fr) | 1985-12-13 |
| CH648023A5 (de) | 1985-02-28 |
| NL8100292A (nl) | 1981-08-17 |
| SE453497B (sv) | 1988-02-08 |
| GB2068729B (en) | 1983-10-19 |
| IT8147604A0 (it) | 1981-01-21 |
| AT380474B (de) | 1986-05-26 |
| GR82326B (en, 2012) | 1984-12-13 |
| FI79840B (fi) | 1989-11-30 |
| US4322424A (en) | 1982-03-30 |
| FR2474493A1 (fr) | 1981-07-31 |
| FI810180L (fi) | 1981-07-25 |
| IT1170638B (it) | 1987-06-03 |
| SE8100341L (sv) | 1981-07-25 |
| ATA32681A (de) | 1985-10-15 |
| IE50884B1 (en) | 1986-08-06 |
| YU14581A (en) | 1983-06-30 |
| IT8147604A1 (it) | 1982-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233106B1 (fr) | (-)-Benzhydrylsulfinylacétamide, procédé de préparation et utilisation en thérapeutique | |
| EP0078785B1 (fr) | Sels d'acide valproîque, leur préparation et leur utilisation | |
| RU2128160C1 (ru) | Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция | |
| CH646412A5 (fr) | Procede de preparation des produits hydrosolubles a base de (+)-catechine et compositions contenant ces produits. | |
| FR2484252A1 (fr) | Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau | |
| TW201039865A (en) | Lyophilized preparations of proteasome inhibitors | |
| FR2696740A1 (fr) | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. | |
| LU83423A1 (fr) | Pneumatique radial pour vehicules tout-terrain | |
| JP6882538B2 (ja) | 注射用組成物 | |
| FR2460669A1 (fr) | Compositions pharmaceutiques a base de rifamycine sv et ses sels adaptes au traitement du rhumatisme articulaire et procede pour leur preparation | |
| CH670448A5 (en, 2012) | ||
| LU83363A1 (fr) | Compositions antitumeurs | |
| FR2505834A1 (fr) | Derives de la thiazolidine | |
| LU83081A1 (fr) | Compositions antitumeurs | |
| BE887220A (fr) | Compositions antitumeurs | |
| BE1001704A3 (fr) | Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique. | |
| EP0449722B1 (fr) | Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés | |
| LU82965A1 (fr) | Nouveaux sels d'addition d'acides du 4'-(9-acridinylamino)methanesulf-m-anisidide,leur procede de production et composition pharmaceutique les contenant | |
| EP3237015B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
| CN109608357B (zh) | 一种治疗口腔炎的药物化合物和组合物及其制备方法 | |
| FR2478092A1 (fr) | Nouveaux sels de l'acide 5-fluoro-2-methyl-1-(p-(methyl-sulfinyl)-benzylidene)-indene-3-acetique, leur procede de preparation et leur application en therapeutique | |
| JP2007106736A (ja) | 注射用の医薬組成物 | |
| FR2491927A1 (fr) | Derives de cephalexine solubles dans l'eau, et procede pour leur preparation | |
| FR2507892A1 (fr) | Compositions antibronchospastiques contenant un sel de theophylline avec un acide amine et leur preparation | |
| CH665634A5 (en) | Stable soluble catechin complexes - with a double salt of L-lysine, for liver protection and digestive ulcers |